{
  "id": "07f4104e87f2adaa",
  "title": "vTv Therapeutics and M42 IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health",
  "description": "20251218T214500Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2025/12/19/tmt-newswire/globenewswire/vtv-therapeutics-and-m42s-iros-announce-submission-of-phase-2-clinical-study-protocol-for-cadisegliatin-in-type-2-diabetes-to-the-united-arab-emirates-department-of-health/2246611",
  "published_at": "20251218T214500Z",
  "fetched_at": "2025-12-19T00:23:08.544189+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2025/12/19/tmt-newswire/globenewswire/vtv-therapeutics-and-m42s-iros-announce-submission-of-phase-2-clinical-study-protocol-for-cadisegliatin-in-type-2-diabetes-to-the-united-arab-emirates-department-of-health/2246611",
    "url_mobile": "https://www.manilatimes.net/2025/12/19/tmt-newswire/globenewswire/vtv-therapeutics-and-m42s-iros-announce-submission-of-phase-2-clinical-study-protocol-for-cadisegliatin-in-type-2-diabetes-to-the-united-arab-emirates-department-of-health/2246611/amp",
    "title": "vTv Therapeutics and M42 IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health",
    "seendate": "20251218T214500Z",
    "socialimage": "https://www.manilatimes.net/manilatimes/uploads/images/2025/12/19/873635.jpg",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}